Top Analyst Reports for HSBC, Abbott & Shell

Thursday, December 4, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including HSBC Holdings plc (HSBC), Abbott Laboratories (ABT) and Shell plc (SHEL), as well as a micro-cap stock Oak Valley Bancorp (OVLY). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Jobless Claims Puzzlingly Light, Lowest in 3 YearsToday's Featured Research ReportsHSBC’s shares have outperformed the Zacks Banks - Foreign industry over the past year (+60.2% vs. +51.2%). The company’s stock performance reflects strong shareholder returns and the success of its Asia pivot strategy despite macroeconomic headwinds. A robust capital position and an expansive global footprint will support financials. As part of its focus on optimizing returns, the company is divesting operations in underperforming regions and has exited retail banking across multiple markets. Though these moves position it for improved operating efficiency, they are likely to temporarily weigh on revenue growth. This, along with subdued loan demand, presents a near-term woe. Elevated costs tied to efforts to expand market share will hurt profits. Yet, business simplification and restructuring initiatives will fuel long-term growth. HSBC's partnership with Mistral AI is in sync with its restructuring plan and will help improve efficiency.(You can read the full research report on HSBC here >>>)Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+10.1% vs. -0.7%). The company’s strong pipeline continues to open up new opportunities, supporting its 2025 outlook. The Medical Devices arm remains a key growth driver, led by the FreeStyle Libre CGM franchise, including the upcoming dual-analyte sensor integrating glucose and ketone monitoring. In Diagnostics, Abbott’s Alinity platforms and Point of Care tests are driving growth outside China, even as VBP-related pricing and volume pressures continue to create a drag. Abbott remains optimistic about its biosimilar strategy, which is expected to boost EPD sales. Within Nutrition, Abbott gains traction, driven by a strong Adult Nutrition and innovation across Ensure and Glucerna brands. Yet, persistent challenges in the Diagnostics, along with tariff impacts, FX fluctuations, and macroeconomic headwinds, continue to weigh modestly on overall growth.(You can read the full research report on Abbott here >>>)Shell’s shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+21.9% vs. +10.6%). This London-based oil supermajor looks fairly balanced at the moment. The company’s third quarter 2025 results highlight resilience and disciplined execution across its portfolio. Strong LNG performance, robust upstream output from projects like Whale and Mero showcase solid cash generation and shareholder commitment. Strategic divestments and targeted reinvestments underscore capital discipline and support long-term transition goals. However, revenue decline alongside rising operating costs is pressuring margins. Chemical and product earnings plunged 65%, revealing downstream weakness, and renewables remain minimally profitable. With stable fundamentals offset by cyclical and structural headwinds, a neutral stance is justified—balancing solid financial health against uneven growth and energy-transition uncertainty.(You can read the full research report on Shell here >>>)Shares of Oak Valley have underperformed the Zacks Banks - West industry over the past year (-6.4% vs. -5%). This microcap company with market capitalization of $235.54 million is witnessing headwinds which include margin pressure from rising deposit costs, a 10% jump in non-interest expenses, and sluggish 0.6% loan growth. CRE loans account for 87% of the portfolio, exposing the bank to sector-specific risk. Additionally, $32.4 million in unrealized securities losses have weighed on book value. Nevertheless, Oak Valley Bancorp posted strong liquidity growth in 2025, with cash surging 46.5% to $247.2 million, supported by 4.7% deposit growth and a 5% rise in total assets. Credit quality remains pristine, with zero non-accrual loans and minimal charge-offs, reflecting disciplined underwriting. Strategic expansion into Downtown Lodi boosts regional market presence and supports long-term growth. Dividend payouts rose 33% year over year, underlining a shareholder-friendly capital approach.(You can read the full research report on Oak Valley here >>>)Other noteworthy reports we are featuring today include Synopsys, Inc. (SNPS), Exelon Corp. (EXC) and Ubiquiti Inc. (UI). Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadExpansion Efforts, Restructuring to Support HSBC Holdings (HSBC)Abbott (ABT) Banks on Solid EPD Prospects, Nutrition SalesStrong Balance Sheet Supporting Sustainable Growth Aids Shell (SHEL)Featured ReportsRegulated Investments and Cost Mangement Aid Exelon (EXC)Per the Zacks analyst Exelon's cost management initiatives will have positive impact on margins and its planned $38B investments through 2028 will strengthen its operation.Balanced Operating Model Aids PulteGroup (PHM) Amid Housing WeaknessPer the Zacks analyst, PulteGroup's balanced approach between build-to-order and spec sales and incentive offerings bodes well. However, a weak housing market and macro risks hurt prospects.Strategic Acquisitions Support Franklin (BEN) Amid Cost PressurePer the Zacks analyst, Franklin's strategic acquisitions, including the recent Apera Asset Management deal, will boost assets under management (AUM). Yet, elevated expenses remain a concern.Gap (GAP) Shines on Strong Momentum Across Key BrandsPer the Zacks analyst, Gap benefited from robust performances at Old Navy, Gap and Banana Republic, reflecting rising brand relevance, improved execution and expanding market share gains.V.F. Corp (VFC) Gains From Outdoor Unit, Vans Brand Struggles PersistPer the Zacks analyst, V.F. Corp is gaining momentum with strong Outdoor performance and disciplined Reinvent execution, though Vans weakness and margin pressures continue to weigh on results overall.Client-Centrism Aids CRA International (CRAI), Liquidity LowPer the Zacks analyst, CRA International's client-first strategy drives improved financial performance and bolsters market sentiment. Low liquidity is concerning.Synopsys (SNPS) Banks on Strong Product Menu, Contract WinsPer the Zacks analyst, Synopsys' focus on strengthening its product portfolio is helping it cater to the growing demand in the EDA market. Deal wins at leading semiconductor companies is a tailwind.New UpgradesUbiquiti (UI) Rides on Strength in Enterprise Technology SegmentPer the Zacks analyst, solid traction in the Enterprise Technology segment, backed by the growing proliferation of IoT devices across industries, will likely drive Ubiquiti's margin.Enterprise AI Demand and Product Expansion Aid GitLab (GTLB) ProspectsPer the Zacks Analyst, Gitlab benefits from expanding its product portfolio and strong enterprise demand for its AI-native DevSecOps platform.EverQuote (EVER) Boasts Revenue Growth, Solid Balance SheetPer the Zacks analyst, consumer traffic, quote request volume and innovative advertiser products and services drive EverQuote revenues. Its strong balance sheet enables it to fulfill debt obligations.New DowngradesNovo Nordisk Experiences Global Slowdown Amid Intense CompetitionPer the Zacks Analyst, NVO's growth prospects are hurting as Wegovy, Ozempic face slowing sales amid rising competition in the global obesity market.Declining Backlogs, Rising Operating Expenses to Ail THOR (THO)Per the Zacks analyst, a decline in backlog is likely to hurt THOR's top-line growth. An uptick in SG and A expenses as a percentage of sales is likely to impact its margin performance.Geopolitical Risks and Industry Uncertainty to Pressure Avanos (AVNS)Per the Zacks analyst, Avanos continues to face pressure from geopolitical headwinds and ongoing healthcare industry uncertainty. Persistent forex volatility and macro challenges also persist.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelon Corporation (EXC): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PulteGroup, Inc. (PHM): Free Stock Analysis Report HSBC Holdings plc (HSBC): Free Stock Analysis Report Oak Valley Bancorp (CA) (OVLY): Get Free Report Ubiquiti Inc. (UI): Free Stock Analysis Report Shell PLC Unsponsored ADR (SHEL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks